Genelux · pitchdeck
Genelux | Investor Presentation Deck | 38 slides
38 pages · 3 arc beats · 2 loops
Genelux | Investor Presentation Deck | 38 slides
Genelux · 2023-10 arc beats above · slides in the middle · loops below · scroll → 2 LOOPS
12468101214161820222426283032343638
Deck intelligence map
3 coverage by narrative range · generated from this deck JSON
Narrative range 38 total
Metadata
Components
Metrics
Tools
Frameworks
Beats
Loops
Problem (Identify pain) 3 slides 100% 3/3 slides 100% 3/3 slides · 11 hits — 0/3 slides
33.3% 1/3 slides — 0/3 slides
100% 3/3 slides — 0/3 slides
Agitate (Make it worse) 6 slides 100% 6/6 slides 100% 6/6 slides · 32 hits — 0/6 slides
16.7% 1/6 slides 83.3% 5/6 slides 100% 6/6 slides 100% 6/6 slides Solution (Provide relief) 29 slides 100% 29/29 slides 100% 29/29 slides · 158 hits — 0/29 slides
27.6% 8/29 slides · 9 hits 27.6% 8/29 slides 100% 29/29 slides 10.3% 3/29 slides Slide inventory
38 every slide · same image gating as the playbook
01
Includes company logo, tagline, and date.front_matter
Open slide detailBeat · Problem (Identify pain)
04
The slide uses a three-column layout to highlight key value propositions of the Olvi-Vec technology.present_solution
05
The slide uses a Gantt-style visualization to show clinical trial stages for multiple drug candidates.plan_implementation
06
Uses a process diagram to illustrate the transition from cold to hot tumor states via viral infection.present_solution
07
The central diagram shows a biological mechanism comparing 'Absence of Effector T Cells' (Platinum resistant) vs 'Presence of Effector T Cells' (Platinum sensitpresent_solution
08
The slide uses a timeline to establish market maturity and investor confidence.show_traction
09
The slide uses a list-based comparison and a logo-grid to frame the competitive landscape.compare_peers
10
The slide uses a pyramid diagram to represent the evolution of oncolytic virus technology, with Genelux's platform at the top.present_solution
Open slide detailBeat · Solution (Provide relief)
11
The slide uses a document-style callout for key takeaways and a vertical icon-list for clinical data points.show_traction
Open slide detailBeat · Solution (Provide relief)
12
The slide uses a process-flow layout to show the trial design and its validation through publications and follow-up trials.show_traction
Open slide detailBeat · Solution (Provide relief)
13
Data table presents ORR, Duration of Response, CA-125 response, PFS, and OS across patient subgroups.show_traction
Open slide detailBeat · Solution (Provide relief)
14
Waterfall plot and spider plot showing patient-level clinical outcomes.show_traction
Open slide detailBeat · Solution (Provide relief)
15
The slide uses a series of bar charts to compare PFS across multiple treatment regimens for three specific patients (15B-01, 15B-15, 15B-17).show_traction
Open slide detailBeat · Solution (Provide relief)
16
Kaplan-Meier survival curve showing superior performance of VIRO-15 compared to historical 4th line treatment data.show_traction
Open slide detailBeat · Solution (Provide relief)
17
The chart compares cross-trial data; the footnote explicitly warns against direct comparison due to protocol differences.summarize
Open slide detailBeat · Solution (Provide relief)
18
The slide outlines a clinical trial protocol for Olvi-Vec in ovarian cancer.plan_implementation
Open slide detailBeat · Solution (Provide relief)
19
Includes Kaplan-Meier survival curves and dose escalation scatter plots for two distinct patient groups.show_traction
Open slide detailBeat · Solution (Provide relief)
20
Includes specific patient case reports (Pt #21A-06 and Pt #21A-04) as evidence of efficacy.show_traction
Open slide detailBeat · Solution (Provide relief)
21
Includes a bio for Benny Li, PhD, CEO of Newsoara.show_traction
Open slide detailBeat · Solution (Provide relief)
22
The slide highlights a strategic partnership, funding, and commercial rights split between US and Greater China markets.show_traction
Open slide detailBeat · Solution (Provide relief)
23
The slide highlights a combination therapy approach involving oncolytic immunotherapy and adoptive cell therapy.present_solution
Open slide detailBeat · Solution (Provide relief)
24
The slide uses a map of the US as a background to anchor the market sizing to a specific geography.size_opportunity
25
The slide highlights physical assets and operational capacity.present_solution
26
The slide uses a hub-and-spoke style layout to show the four pillars supporting the central launch strategy.plan_implementation
27
The slide categorizes the platform's capabilities into therapeutic genes, immune modularity, and therapeutic antibodies, emphasizing non-GMO status and GLP tox present_solution
Open slide detailBeat · Solution (Provide relief)
28
The slide highlights key defensive moats including patent counts, expiration dates, and lack of royalty obligations.present_solution
Open slide detailBeat · Solution (Provide relief)
29
The slide uses a grid layout to categorize team members into three distinct groups: Executive Team, Board of Directors, and Operations & R&D.other
Open slide detailBeat · Solution (Provide relief)
30
The slide uses a combination of a checklist for past achievements and a timeline arrow for future goals.plan_implementation
Open slide detailBeat · Solution (Provide relief)
31
Includes footnotes regarding market close date and specific financing obligations.analyze_data
Open slide detailBeat · Solution (Provide relief)
33
The slide indicates this is an appendix section of an October 2023 corporate presentation.appendix
Open slide detailBeat · Solution (Provide relief)
34
The slide lists key advisors, some of whom also hold executive roles (CEO, CMO, CFO) within the company.other
Open slide detailBeat · Solution (Provide relief)
35
Includes microscopic imagery of patient samples (Pt.#15A-01 and Pt.#15A-11) showing longitudinal progression of treatment.show_traction
Open slide detailBeat · Solution (Provide relief)
36
The slide compares pre- and post-treatment biopsies for three patients (15A-16, 15A-18, 15A-23) using both visual microscopy and quantitative infiltration histoshow_traction
Open slide detailBeat · Solution (Provide relief)
37
The slide uses a combination of a bar chart (ELISPOT data) and a line chart (SLD over time) to show clinical efficacy.show_traction
Open slide detailBeat · Solution (Provide relief)
38
The slide uses clinical study data (VIRO-15, NCT01443260) to support its claims.present_solution
Open slide detailBeat · Solution (Provide relief)